A National Program for Severe Asthma: The Canadian Severe Asthma Network (CSAN)
The Canadian Severe Asthma Network (CSAN) was developed to gain a better understanding of the clinical, environmental, socio-economic, work-related, and biological characteristics of severe asthmatics (SA) that may account for poor response to clinically available therapies for asthma.
This network of clinical and basic researchers will be a means by which Canadian investigators can develop and conduct research in this small patient group, which could lead to better clinical management of SA.
Patient information will be entered into the CSAN database (created by PI Dr. Vethanayagam in connection with Mr. Jack Yeung) and will help researchers and doctors from multiple hospitals and universities across Canada to understand this subpopulation of asthmatics better. It will help to answer questions regarding SA epidemiology, asthma education, inflammatory monitoring, risks of near fatal asthma (NFA), symptom perception, changes in lung structure and function, co-morbidities, and the effectiveness of developing regional severe asthma clinics. Two of the early projects the investigators will be working on are psychosocial co-morbidities in asthma and medication coverage related to asthma.
There will also be biobanking of sputum samples and/or bronchoscopy samples (such as BALs & lung washings) that are being obtained for clinical purposes. Also, for those consented for biobanking blood and urine will be collected, separate from clinical care, and stored in the biobank. The Canadian Biosample Repository (CBSR) will be storing our biobanked samples. The investigators will be following the CBSR policies for storage and security. Tissue research will be conducted in the future, and separate ethics approval will be obtained for each project.
Severe Persistent Asthma
|Study Design:||Observational Model: Case Control
Time Perspective: Prospective
|Official Title:||A National Program for Severe Asthma: The Canadian Severe Asthma Network|
If consented to by the patient, extra clinical specimens - sputum plugs, sputum supernatant, blood and urine will be stored. If patients undergo a clinical bronchoscopy, mucosal biopsies x 2 and bronchoalveolar lavage will be stored.
|Study Start Date:||June 2010|
|Study Completion Date:||August 2012|
|Primary Completion Date:||August 2012 (Final data collection date for primary outcome measure)|
Main study group
Show Detailed Description
Please refer to this study by its ClinicalTrials.gov identifier: NCT00954850
|University of Alberta Hospital|
|Edmonton, Alberta, Canada, T6G 2B7|
|Principal Investigator:||Dilini Vethanayagam, MD||University of Alberta|